Bachem renews Goserelin agreement with AZ

Published: 9-Aug-2011
Ingredients Finance

Will continue supply for the next seven years


Swiss biochemicals supplier Bachem has renewed an agreement with AstraZeneca for the supply of Goserelin for the next seven years.

Bachem has been supplying Goserelin to AstraZeneca for more than 20 years.

AstraZeneca uses the product in Zoladex, its injectable gonadotropin releasing hormone super-agonist.

With headquarters in Bubendorf and affiliates in Europe and the US, Bachem specialises in the process development and manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients, as well as innovative biochemicals for research purposes.

  • Companies:
  • Bachem
  • AstraZeneca
See more

You may also like

Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Read more
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium

Trending Articles

  1. Adult vaccination programmes deliver significant socio-economic benefits, study finds The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
  2. Prima BioMed announces new product candidate IMP761: a LAG-3 agonist antibody Prima BioMed announces that it has developed a new early stage product candidate, a humanised IgG4 monoclonal antibody to be known as IMP761
  3. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  4. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  5. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium
Research & Development

AstraZeneca to acquire Amolyt Pharma for up to $1.05 billion

The acquisition will facilitate the development of novel therapeutics for rare endocrine and related diseases
Finance

AstraZeneca to acquire vaccine company Icosavax

Building on expertise in RSV prevention, the acquisition will accelerate the company's ambition to deliver a portfolio of protective interventions to address high unmet needs in infectious diseases
Ingredients

Nanoform grants Global STARMAP AI License to AstraZeneca

Nanoform Finland, an innovative nanoparticle medicine-enabling company has announced that it has granted AstraZeneca Plc a global online STARMAP licence
Manufacturing

Swiss biomanufacturing sector continues to thrive in 2023

Seigfried, Lonza, ten23 health, Bachem and Dottikon all announce major expansions
Ingredients

Therapeutic: capivasertib as an anticancer agent

Although endocrine therapies are a cornerstone of many treatments for hormone-dependent cancers, resistance to first-line CDK4/6 inhibitors and endocrine therapies often develop. This leaves only limited treatment options and, as a result, alternatives are much needed
Ingredients

Therapeutic: eplontersen for ATTRv-PN

Hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) is the result of a misfolded mutated protein — transthyretin (TTR) — accumulating in the peripheral nerves
Subscribe now